Analyses of discovered cancer-driving nucleotides (CDNs) reveal their evolutionary, biochemical, and therapeutic characteristics that are often shared among multiple cancer types.
A mathematical model shows that mutations that recur even modestly among cancer patients are cancer driving nucleotides that can be exhaustively identified to serve as targets of cancer therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback